229 related articles for article (PubMed ID: 35537120)
1. Treating people where they are: Nurse-led micro-elimination of hepatitis C in supported housing sites for networks of people who inject drugs in Victoria, Canada.
Selfridge M; Barnett T; Lundgren K; Guarasci K; Milne R; Drost A; Fraser C
Public Health Nurs; 2022 Sep; 39(5):1009-1016. PubMed ID: 35537120
[TBL] [Abstract][Full Text] [Related]
2. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
[TBL] [Abstract][Full Text] [Related]
3. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide.
Tai CM; Yu ML
Kaohsiung J Med Sci; 2024 Feb; 40(2):112-118. PubMed ID: 38010851
[TBL] [Abstract][Full Text] [Related]
5. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study.
Mirzazadeh A; Hosseini-Hooshyar S; Shahesmaeili A; Sharafi H; Shafiei M; Zarei J; Mousavian G; Tavakoli F; Ghalekhani N; Shokoohi M; Khezri M; Mehmandoost S; Shojaei MR; Karamouzian M; Briceno A; Morris MD; Alavian SM; Haghdoost AA; Sharifi H; Page KA
Int J Drug Policy; 2022 Apr; 102():103580. PubMed ID: 35074607
[TBL] [Abstract][Full Text] [Related]
6. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
[TBL] [Abstract][Full Text] [Related]
7. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
8. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
Tatara E; Gutfraind A; Collier NT; Echevarria D; Cotler SJ; Major ME; Ozik J; Dahari H; Boodram B
PLoS One; 2022; 17(3):e0264983. PubMed ID: 35271634
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
Caven M; Baiano CX; Robinson EM; Stephens B; Macpherson I; Dillon JF
J Viral Hepat; 2021 Dec; 28(12):1744-1750. PubMed ID: 34525228
[TBL] [Abstract][Full Text] [Related]
10. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
11. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G
BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867
[TBL] [Abstract][Full Text] [Related]
12. Integration of Hepatitis C and Addiction Treatment in People Who Inject Drugs: The San Patrignano HCV-Free and Drug-Free Experience.
Piselli P; Boschini A; Gianfreda R; Nappo A; Cimaglia C; Scarfò G; Smacchia C; Paoletti R; Duehren S; Girardi E
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543741
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.
Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H
Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914
[TBL] [Abstract][Full Text] [Related]
14. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
15. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
[TBL] [Abstract][Full Text] [Related]
16. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
[TBL] [Abstract][Full Text] [Related]
17. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.
Hsu JT; Hsu PI; Shie CB; Chuah SK; Wu IT; Huang WW; Tang SY; Tsai KF; Kuo LF; Ghose S; Hsu JC; Shih CA
Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334612
[TBL] [Abstract][Full Text] [Related]
19. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
20. Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review.
Hajarizadeh B; Kairouz A; Ottaviano S; Ireland J; Willing A; Cunningham E; Webb P; Colledge-Frisby S; Wheeler A; Leung J; Tran LT; Price O; Vickerman P; Farrell M; Hickman M; Dore GJ; Bergenström A; Degenhardt L; Grebely J
Lancet Glob Health; 2023 Dec; 11(12):e1885-e1898. PubMed ID: 37973339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
